Vanda Pharmaceuticals has paid $100 million to Actelion Pharmaceuticals, a Johnson & Johnson company, for the US and Canada rights to multiple sclerosis drug Ponvory.
The drug, an oral selective sphingosine-1-phosphate receptor 1 (S1P1R) modulator, was approved in 2021 for adults with relapsing forms of multiple sclerosis after showing superior efficacy to standard of care Aubagio (teriflunomide).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.